Clinical proteomics: translating benchside promise into bedside reality.

@article{citeulike:3024528, abstract = {The ultimate goal of proteomics is to characterize the information flow through protein networks. This information can be a cause, or a consequence, of disease processes. Clinical proteomics is an exciting new subdiscipline of proteomics that involves the application of proteomic technologies at the bedside, and cancer, in particular, is a model disease for studying such applications. Here, we describe proteomic technologies that are being developed to detect cancer earlier, to discover the next generation of targets and imaging biomarkers, and finally to tailor the therapy to the patient.}, address = {FDA-NCI Clinical Proteomics Program, Division of Therapeutic Proteins, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA. petricoin@cber.fda.gov}, author = {Petricoin, E. F. and Zoon, K. C. and Kohn, E. C. and Barrett, J. C. and Liotta, L. A. }, citeulike-article-id = {3024528}, doi = {http://dx.doi.org/10.1038/nrd891}, issn = {1474-1776}, journal = {Nature reviews. Drug discovery}, keywords = {proteomics, review}, month = {September}, number = {9}, pages = {683--695}, posted-at = {2008-07-21 15:19:02}, priority = {0}, title = {Clinical proteomics: translating benchside promise into bedside reality.}, url = {http://dx.doi.org/10.1038/nrd891}, volume = {1}, year = {2002} }

TY - JOUR ID - citeulike:3024528 L3 - citeulike-article-id:3024528 TI - Clinical proteomics: translating benchside promise into bedside reality. JF - Nature reviews. Drug discovery VL - 1 IS - 9 SP - 683 EP - 695 AD - FDA-NCI Clinical Proteomics Program, Division of Therapeutic Proteins, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA. petricoin@cber.fda.gov SN - 1474-1776 N2 - The ultimate goal of proteomics is to characterize the information flow through protein networks. This information can be a cause, or a consequence, of disease processes. Clinical proteomics is an exciting new subdiscipline of proteomics that involves the application of proteomic technologies at the bedside, and cancer, in particular, is a model disease for studying such applications. Here, we describe proteomic technologies that are being developed to detect cancer earlier, to discover the next generation of targets and imaging biomarkers, and finally to tailor the therapy to the patient. KW - proteomics KW - review AU - Petricoin, EF AU - Zoon, KC AU - Kohn, EC AU - Barrett, JC AU - Liotta, LA PY - 2002/09// UR - http://dx.doi.org/10.1038/nrd891 ER -